|Day Low/High||1.92 / 2.06|
|52 Wk Low/High||1.38 / 9.95|
Higher lows between now and Labor Day should confirm the end of the correction.
J.P. Morgan initiated coverage on BioCryst Pharmaceuticals (BCRX) with an "overweight" rating and a $20 price target for year-end 2015.
Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a "perilous reversal" (up big yesterday but down big today) candidate
The trading panel looked at Michael Kors' earnings, Microsoft, steel stocks and biotechs.
bioCryst Pharmaceuticals and Arris Enterprises also appear to have more room to run.
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
The most recent short interest data has been released by the NASDAQ for the 07/15/2014 settlement date, which shows a 2,252,345 share increase in total short interest for BioCryst Pharmaceuticals, Inc. , to 7,901,378, an increase of 39.87% since 06/30/2014.
Investors in BioCryst Pharmaceuticals, Inc. saw new options become available this week, for the March 2015 expiration.
The trading panel discussed Friday's rally and what they'll be buying and selling next week.
Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a pre-market mover with heavy volume candidate
BioCryst Pharmaceuticals (BCRX) rose Tuesday after the company announced its experimental drug for treating a rare immune disorder was effective in decreasing the disease's attacks in a mid-stage trial.
In trading on Monday, shares of BioCryst Pharmaceuticals, Inc. crossed below their 200 day moving average of $7.66, changing hands as low as $7.58 per share.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.